Multiple resistance modulators combined with carboplatin for resistant malignancies: A pilot study

Investigational New Drugs

Volumn 15, Issue 4, 1997, Pages 267-277

  Stewart, David J ^a   Goel, Rakesh ^a   Cripps, M Christine ^a   Huan, Susan ^a   Yau, Jonathan ^a   Verma, Shailendra ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Carboplatin; Chemotherapy; Dipyridamole; Ketoconazole; Metronidazole; Novobiocin; Pentoxifylline; Resistance modulators; Tamoxifen

Indexed keywords

CARBOPLATIN; DIPYRIDAMOLE; KETOCONAZOLE; MANNITOL; METRONIDAZOLE; NOVOBIOCIN; PENTOXIFYLLINE; SODIUM CHLORIDE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; UREMIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD VISCOSITY; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS;

EID: 0031405966     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005993705237     Document Type: Article

References (78)

1. Zijlstra JG, de Vries EGE, Mulder NH: Multifactorial drug resistance in adriamycin-resistant human small-cell lung carcinoma cell line. Can Res 47:1780-1784, 1987
2. Volm M, Kastel M, Mattern J, Effert T: Expression of resistance factors (p-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their inter-relationship to proto-oncogene products in renal cell carcinomas. Cancer 71:3981-3987, 1993
3. Raaphorst GP, Yang DP, Grewaal D, Stewart D, Goel R, Ng CE: Analysis of mechanisms of cisplatin resistance in three pairs of human tumour cell lines expressing normal and resistant responses to cisplatin. Oncol Rep 2:1037-1043, 1995
4. de Graeff A, Slebos RJ, Rodenhuis S: Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol 22:325-332, 1988
5. van der Zee AG, Hollema HH, de Bruijn HW, Willemse PH, Boonstra H, Mulder NH, Aalders JG, de Vries EG: Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 58:165-178, 1995
6. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC: Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53:5225-5232, 1993
7. Clement JJ, Johnson RK: Evaluation of radiosensitizers in combination with chemotherapeutic agents in solid tumors. Int J Rad Oncol Biol Phys 8:631-634, 1982
8. Roizin-Towle L, Hall EJ, Piro JP: Oxygen dependence for chemosensitization by misonidazole. Br J Cancer 54:919-924, 1986
9. Murray D, Meyn RE: Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo. Br J Cancer 50:801-808, 1984
10. Taylor YC, Sawyer JM, Hsu B, Brown JM: Mechanisms of melphalan crosslink enhancement by misonidazole pretreatment. Int J Radiat Oncol Biol Phys 10:1603-1607, 1984
11. Mahood JS, Wilson RL: Cytotoxicity of metronidazole (Flagyl) and misonidazole (Ro-07-0582): Enhancement by lactate. Br J Cancer 43:350-354, 1981
12. Stewart DJ, Evans WK: Non-chemotherapeutic agents potentiate chemotherapy efficacy. Can Treat Rev 16:1-40, 1989
13. Lai S-L, Hwang J, Perng R-P, Whang-Peng J: Modulation of cisplatin resistance in acquired-resistant non-small cell lung cancer cells. Oncol Res 7:31-38, 1995
14. Efferth T, Fabry U, Glatte P, Osieka R: Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. J Cancer Res Clin Oncol 121:648-656, 1995
15. Aviado DM, Dettelback HR: Pharmacology of pentoxifylline a hemorheologic agent for the treatment of intermittent claudication. Angiology 35:407-417, 1984
16. Jekunen A, Vick J, Sanga R, Chan TCK, Howell SB: Synergism between dipyridamole and cisplatin in human ovarian cancer cells in vitro. Cancer Res 52:3566-3571, 1992
17. Ali-Osman F, Berger MS, Rajagopal S, Spence A, Livingston RB: Topoisomerase II inhibition and altered kinetics of nitrosourea and cisplatin-induced DNA interstand crosslinks and cytotoxicity in human glioblastoma cells. Cancer Res 53:5663-5668, 1993
18. Rappa G, Lorico A, Sartorelli AC: Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II. Cancer Res 50:6723-6730, 1990
19. Ayesh S, Shao YM, Stein WD: Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316:8-18, 1996
20. Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A: Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem Pharmacol 50:723-726, 1995
21. McClay EF, Albright KD, Jones JA, Christen RD, Howell SB: Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer 55:1018-1022, 1993
22. Sharp SY, Mistry P, Valenti MR, Bryant AP, Kelland LR: Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B. Cancer Chemother Pharmacol 35:137-143, 1994
23. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM: Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urology 151:485-491, 1994
24. Robert J: Proposals for concomitant use of several modulators of multidrug resistance in clinics. Anticancer Res 14:2371-2374, 1994
25. Kim JH, Chung JB, Park IS, Kim BS, Yoo NC, Choi JH, Roh JK, Kim HS, Kwon OH, Lee KS et al.: Combined use of tamoxifen, cyclosporin A, and verapamil for modulating resistance in human hepatocellular carcinoma cell lines. Yonsei Med J 34:35-44, 1993
26. Lyubimov E, Lan L-B, Pashinsky I, Ayesh S, Stein WD: Saturation reversal of the multidrug pump using many reversers in low-dose combinations. Anti-Cancer Drugs 6:727-735, 1995
27. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE: Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 77:348-354, 1991
28. Ishida Y, Shimada Y, Shimoyama M: Synergistic effect of cyclosporin A and verapamil on overcoming vincristine resistance of multidrag-resistant cultured human leukemia cells. Jap J Cancer Res 81:834-841, 1990
29. Hu XF, Martin TJ, Bell DR, de Luise M, Zalcbert JR: Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50:2953-2957, 1990
30. Osann K, Sweet P, Slater LM: Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro. Cancer Chemother Pharmacol 30:152-154, 1992
31. Ross DD, Wooten PJ, Tong Y, Cornblatt B, Levy C, Sridhara R, Lee EJ, Schiffer CA: Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells in cyclosporin A and cremophor EL. Blood 83:1337-1347, 1994
32. Brooks SE, Korbut TT, Dupuis NP, Holden SA, Teicher BA: Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin. Cancer Chemother Pharmacol 36:431-438, 1995
33. Stewart DJ, Goel R, Cripps MC, Yau J, Huan S, Tomiak E, Davies RA, Dulude H, Gallant G: Concurrent use of multiple chemotherapy resistance modulators with etoposide in patients with resistant malignancies. Internal J Oncol 11:709-716, 1997
34. Stewart DJ, Cripps MC, Goel R et al.: Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies. Cancer Chemother Pharmacol, in press
35. Stewart DJ, Dahrouge S, Agboola O, Girard A: Cranial radiation and concomilant cisplatin and mitomycin-C plus resistance modulators for malignant gliomass. J Neuro-Oncol 32:161-168, 1997
36. Reed E: Platinum analogs. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 4th edition. JB Lippincott Co, Philadelphia, 1993, pp 390-400
37. McEvoy GK (ed): Novobiocin sodium. In: American Hospital Formulary Service (AHFS) Drug Information 89. American Society of Hospital Pharmacists, Bethesda, MD, 1989, pp 325-326
38. Gillis MC (ed): Compendium of Pharmaceuticals and Specialties, 31st edition. Canadian Pharmaceutical Association, Ottawa, ON, 1996
39. Burke AM, Quest DO, Chien S, Cerri C: The effects of mannitol of blood viscosity. J Neurosurg 55:550-553, 1981
40. Jafar JJ, Johns LM, Mullan SF: The effect of mannitol on cerebral blood flow. J Neurosurg 64:754-759, 1986
41. Jain RK: Determinants of tumor blood flow: a review. Cancer Res 48:2641-2658, 1988
42. Bergan T: Antibacterial activity and pharmacokinetics of nitromidazoles. A review. Scand J Infect Dis (Suppl) 46:64-71, 1985
43. Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH: Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokin 23:328-364, 1992
44. Coyle P, Philcox JC, Rofe AM: Corticosterone enhances the zinc and interleukin-6-mediated induction of metallothionein in cultured rat hepatocytes. J Nutrition 123:1464-1470, 1993
45. Lybak S, Wennerberg J, Kjellen E, Pero RW: Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck. Anti-Cancer Drugs 2:375-382, 1991
46. Israel R, O'Mara V, Austin B, Bellucci A, Meyer BR: Metoclopramide decreases renal plasma flow. Clin Pharm Therapeut 39:261-264, 1986
47. Stewart DJ, Dulberg C, Mikhael NZ, Redmond MD, Montpetit VAJ, Goel R: Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40:293-308, 1997
48. Stewart DJ, Dulberg C, Molepo JM, Mikhael NZ, Montpetit VAJ, Redmond MD, Goel R: Factors affecting human autopsy kidney cortex and kidney medulla platinum concentrations after cisplatin. Cancer Chemother Pharmacol 34:14-22, 1994
49. Lee FYF, Workman P: Altered pharmacokinetics in the mechanism of chemosensitization: Effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumor activity and acute toxicity of selected nitrogen mustards. Cancer Chemother Pharmacol 17:30-37, 1986
50. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH: Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 37:266-270, 1996
51. Beksac M, Akan H, Koc H, Ilhan O, Erturk S, Guneyli A, Ikizunal Y, Sardas OS: P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporin A containing protocols. Med Oncol & Tumor Pharmacother 9:101-105, 1992
52. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporin as a chemotherapy-resistant modifier in acute leukemia. J Clin Oncol 11:1652-1660, 1993
53. Sotomatsu M, Yugami S-I, Shitara T, Kuroume T: Dipyridamole enhancement of drug sensitivity in acute lymphoblastic leukemia cells. Am J Hematol 43:251-255, 1993
54. Sonnoveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Sociu S, Zittoun R, Lowenberg B, Nooter K: Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Lancet 340:255-259, 1992
55. Chan HSL, Koren G, Thorner PS, Verjee Z, Haddad G, Giesbrecht E, Greenberg ML, Ling V, Gallie BL: Reversal of multidrug resistance (MDR) in retinoblastoma (RB) by cyclosporin A (CsA). Proc Am Soc Clin Oncol 11:375, 1992
56. Stiff P, Bayer R, Sosman J, Peace D, Rad N, Kinch L: High dose chemotherapy with marrow rescue and cyclosporin A: a combined modality approach to overcome drug resistance in solid tumors. Proc Am Soc Clin Oncol 12:132, 1993
57. Manetta A, Boyle J, Berman M, DiSaia PJ, Lentz S, Liao SY, Mutch D, Slater L: Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer 73:196-199, 1994
58. Baradakji Z, Jolivet J, Langelier Y, Besner JG, Ayoub J: 5-fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 18:140-144, 1986
59. Dalley D, Brigham B: Phase I/II study of oral etoposide and modulation of drug resistance with ketoconazole (KCZ) in small-cell lung cancer (SCLC). Fourth International Congress on Anti-Cancer Chemotherapy, p 85, Paris 1993
60. Verweij J, Herweijer H, Oosterom R, van der Burg MEL, Planting ASTh, Seynaeve C, Stoter G, Nooter K: A phase I study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64:361-364, 1991
61. Manzano RG, Alonso G, Foncillas JG, Brugarolas A: Cyclosporin A (CsA) plus doxorubicin (dox) containing chemotherapy in adult anthracycline resistant solid tumors (ARST): a phase I clinical study. Proc Am Soc Clin Oncol 12:A385, 1993
62. Wilson JKV, Fischer PH, Tutsch K, Remick SG, Grem JL, Bruggink L, Alberti D, Simon K, Trump DL: Dipyridamole modulates methotrexate cytotoxicity: Results of a clinical trial based upon inhibition of nucleoside salvage. Proc Am Soc Clin Oncol 6:36, 1987
63. Higano C, Livingstone R: Methotrexate (MTX) and oral dipyridamole (DP) in the treatment of refractory solid tumors: A phase I-II study. Proc Am Soc Clin Oncol 6:23, 1987
64. Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ: A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. Am J Clin Oncol (CCT) 17(1):10-13, 1994
65. Panella T, Strozyk W, Fine R: Phase I study of alpha-interferon 2b (IFN) with hydroxyurea (HU), tamoxifen (TAM), and streptozotocin (STZ) as combined modulators of drug resistance with BCNU. Proc Am Soc Clin Oncol 14:A402, 1995
66. Raschko J, Doroshow JH, Ahn C, Carroll M, Akman S, Coluzzi P, Hamasaki V, Leong L, Margolin K, Morgan R: Phase I study of multidrug resistance reversal: Biochemical modulation of etoposide (VP16) and carboplatin (CBDCA) with dipyridamole (DP), prochlorperazine (Comp), and cyclosporin A (CSA). Proc Am Soc Clin Oncol 13:A444, 1994
67. Wishart GC, Harnett A, Kerr DH, Paul J, Machem MA, Soukop M, Leonard RCF, Kaye SB: A randomised placebo controlled trial of quinidine as a resistance modulators in patients with advanced breast cancer treated with epirubicin. Proc Am Soc Clin Oncol 12:A33, 1993
68. Stewart DJ, Molepo M, Green RM, Montpetit VAJ, Hugenholtz H, Lamothe A, Mikhael NZ, Redmond MD, Goel R: Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 71:598-604, 1995
69. Assem M, Bonvalot S, Beltramo JL, Garrido C, Dimanche-Boitrel MT, Genne P, Rebibou JM, Caillot D, Chauffert B: Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells. Br J Cancer 70:631-635, 1994
70. Stewart DJ, Raaphorst P, Yau J, Beaubien AR: Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 14:115-130, 1996
71. Stewart DJ, Futter N, Irvine A, Danjoux C, Moors D: Mitomycin-C and metronidazole in the treatment of advanced renal cell carcinoma. Am J Clin Oncol 10:520-522, 1987
72. Stewart DJ, Maroun JA, Lefebvre B, Heringer R, Crook AF: Mitomycin-C plus metronidazole in advanced carcinoma of the breast. Breast Cancer Res Treat 5:189-194, 1985
73. Stewart DJ, Maroun JA, Young V, Crook AF, Hopkins HS, Yan RC, Richart MT, Hugenholtz H, Belanger R, Heringer R, Lefebvre B, Laframboise G: Feasibility study of combining metronidazole with chemotherapy. J Clin Oncol 1:17-23, 1983
74. Stewart DJ, Benoit B, Richard MT, Hugenholtz H, Dennery J, Russell N, Peterson E, Grahovac Z, Belanger G, Maroun JA, Young V: Treatment of malignant gliomas in adults with BCNU plus metronidazole. J Neuro-oncol 2:53-58, 1984
75. Stewart DJ, Cripps MC, Lamothe A, Laframboise G, Odell P, Gerin-Lajoie J: Doxorubicin plus metronidazole in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 16:113-116, 1993
76. Stewart DJ, Evans WK, Logan D: Addition of pentoxifylline plus nifedipine to chemotherapy in patients with cisplatin-resistant cancers of the lung and other sites. Am J Clin Oncol 17:313-316, 1994
77. Goel R, Stewart DJ: Phase I study of alternating cycles of high dose combination chemotherapy with different mechanisms of action to overcome drug resistance. Proc Am Soc Clin Oncol 15:1575, 1996
78. Stewart DJ, Goel R, Gertler S, Huan S, Yau J, Tomiak E, Cripps C, Prosser A, Soltys K: Multiple chemotherapy drugs with differing mechanisms of action to overcome passive resistance. Proc Am Soc Clin Oncol 15:405, 1996